AXON Neuroscience, an industry leading, clinical stage biotech at the forefront of treatment and prevention of Alzheimer’s disease, has announced the results of the Phase II trial for AADvac1, its first-in-class vaccine to slow down the progression of Alzheimer’s Disease. The Phase II ADAMANT trial was designed as a randomized, double-blinded, placebo- controlled trial in mild Alzheimer’s Disease. The primary objective was safety, with secondary objectives to evaluate immunogenicity, efficacy on clinical outcomes and key biomarkers. Axon studied AADvac1 on 196 patients in eight European countries over 24 months, in order to prove the concept of disease modifying effect of the vaccine and to inform the design of future confirmatory studies.
We are a one-stop shop Healthcare Advisory & Consulting boutique and we help businesses with funding, market access, business strategy, distribution.
AI Alzheimer antibodies Biosimilar Cancer cardiovascular cell therapy CE Mark clinical trial Diagnostics Digital Health Drug Discovery EpiVax' FDA FDA approval funding fundraising HIV Immunogenicity Immunotherapies INVO Bioscience Licensing M&A medical device microbiome Neuro next-gen sequencing NGS PathAI pathology Pepticom peptides pharma PierianDx RNA robots Shape Therapeutics skin software SurgiMab Therapeutics therapies USA VIrology Virus